[BioSnap] Lunit supplies AI video analysis solution to Saudi government

Lunit [328130] supplies artificial intelligence (AI) video analysis solutions to the Saudi Arabian government.

Rocket Healthcare [376900] announced that it will begin its AI long-term regeneration project in earnest through an investment of over 60 billion won.

Lunit announced on the 10th that it will supply the chest The supply is made through a subsidiary of Saudi Telecom Group, a Saudi Arabian telecommunications company. This company serves as the system integrator, and Lunit supplies AI solution licenses.

Rokit Healthcare announced on the 10th that it will invest 65.4 billion won by 2028 in six projects, including skin regeneration, cartilage regeneration, kidney regeneration, hair regeneration, AI prediction, and reverse aging. Specific areas of investment include clinical development of kidney regeneration, clinical trials of cartilage regeneration, and expansion of commercialization of skin regeneration. The company plans to build an integrated medical platform that leads to ‘AI prediction-prevention-regeneration’ through investment.

Vivozon Pharmaceuticals announced on the 10th that its affiliate Vivozon has begun administering the first patient in the U.S. phase 1b clinical trial of 'VVZ-2471', an oral non-narcotic analgesic candidate. The purpose of the clinical trial is to evaluate the safety and tolerability of repeated medication in patients with opioid use disorder. Opioid refers to opiate painkillers. Vivozon announced that it has completed phase 2 clinical trials in Korea for post-herpetic neuralgia and is analyzing the data.

HLB Pep [196300] announced on the 10th that the domestic finished drug produced by supplying leuprorelin acetate raw drug product received product approval from Mexican authorities. This is the first time that a finished drug using HLB Pep's raw drug substance has been approved by overseas regulatory authorities. Leuprorelin is a peptide hormone used in the treatment of prostate cancer.